Asset Details
Do you wish to reserve the book?
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
Do you wish to request the book?
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
2016
Overview
ObjectivesWhether the increased risk of comorbidities, such as cardiovascular disease, in rheumatoid arthritis (RA) can be reverted by particular antirheumatic therapies, or response to these, is unclear but of critical clinical importance. We wanted to investigate whether response to tumour necrosis factor inhibitors (TNFi) translates into a reduced risk for acute coronary syndrome (ACS).MethodsA cohort of patients with RA initiating a first TNFi 2001–2012 was identified in the Swedish Biologics Register. The association between European League Against Rheumatism (EULAR) response after 3–8 months of treatment (assessed using the first, the best and the measurement closest to 5 months, respectively), and the risk of incident ACS during the subsequent year was analysed in Cox regression models. Adjustments included cardiovascular risk factors, joint surgery, RA duration, education and work disability.ResultsDuring 6592 person-years among TNFi initiators (n=6864, mean age 55 years, 77% women), 47 ACS occurred. The adjusted HRs (95% CI), which were similar to the crude HRs, of the 1-year risk of ACS among EULAR good responders compared with non-responders were 0.5 (0.2 to 1.4), 0.4 (0.2 to 0.9) and 0.5 (0.2 to 1.2), for the first, the best and the evaluation closest to 5 months, respectively. EULAR moderate responders had equal risk to that of EULAR non-responders, who, compared with the general population referents (n=34 229), had a more than twice the risk of ACS. For good responders, there was no statistically significant difference in risk versus the general population.ConclusionsOptimised RA disease control has the potential to revert otherwise increased risks for ACS in RA.
Publisher
Elsevier Limited
Subject
/ Acute Coronary Syndrome - epidemiology
/ Acute Coronary Syndrome - etiology
/ Acute Coronary Syndrome - prevention & control
/ Adult
/ Aged
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Rheumatoid - complications
/ Arthritis, Rheumatoid - drug therapy
/ Autoimmunitet och inflammation
/ Autoimmunity and Inflammation
/ Biological Products - therapeutic use
/ evoo mll
/ Female
/ Humans
/ Male
/ p44
/ Patients
/ register
/ Tumor Necrosis Factor-alpha - antagonists & inhibitors
/ v38
